---
title: "Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296444477.md"
description: "Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca with a price target of p16,300.00, while shares closed at p12,050.00. UBS also issued a Buy rating, whereas Deutsche Bank maintained a Sell rating."
datetime: "2026-08-20T06:25:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296444477.md)
  - [en](https://longbridge.com/en/news/296444477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296444477.md)
generator: "portal-rs"
---

# Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca yesterday and set a price target of p16,300.00. The company’s shares closed yesterday at p12,050.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Autolus Therapeutics. According to TipRanks, Sharma has an average return of 3.5% and a 52.54% success rate on recommended stocks. 

In addition to Goldman Sachs, AstraZeneca also received a Buy from UBS’s Colin White in a report issued yesterday. However, on the same day, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [AUTL.US](https://longbridge.com/en/quote/AUTL.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [Goldman Sachs Remains a Buy on arGEN X (0QW0)](https://longbridge.com/en/news/296183571.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**